

For our investors, current news and developments in key areas of the medical diagnostics field.

COMPANY NEWS

Facility

The Epinex company facility in Irvine has significantly increased its manufacturing operations. We have recently acquired the equipment needed to initiate pilot production of rapid tests while we prepare for FDA establishment registration.



Reception Area

The Dry Room and Wet Lab have been outfitted with State-of-the-Art apparatus from Biodot to spray, dry and cut the rapid test strips with the antibodies, reagents and other compounds that make up our unique product line.



Dry Lab

Epinex Presents At Venture Capital Forums In Southern California

EpInex was an invited presenter the 11th annual LARTA Venture Forum, held at the Wilshire Grand Hotel in Los Angeles in May and at the TIE SoCal Venture Presentation Forum held at UC Irvine in July.



Dr. Wang Addresses Investors and Guests at EpInex Open House Facility Tour

EpInex Welcomes Dr. Ping Wang to Advisory Board

The Company is extremely pleased to announce that **Dr. Ping Wang**, one of the leading names in diabetes research and treatment worldwide, has joined our Advisory Board. Dr. Wang is the Director of the Joslin Diabetes Center at the University of California, Irvine, the world leader in diabetes research and care. He is also the Division Chief of the Endocrinology, Diabetes, and Metabolism section of the Department of Medicine at the University of California, Irvine.

A diabetes and metabolism specialist, Dr. Wang earned his medical degree from Kaohsiung Medical College, Taiwan, and pursued his subspecialty fellowship in endocrinology and metabolism at the Joslin Diabetes Center at Harvard Medical School. His research interests include insulin-like growth factor, heart, diabetes, and diabetes complications.

EpInex Patents on the Web

WIPO:
<http://wipo.int/ipdl/en/search/pct/search-simp.jsp>; search term: 'epinex'

European Community:
<http://v3.espacenet.com/textdoc?IDX=WO2005031356>

PATENT NEWS

The Company's patent for the Rapid Test for Glycated Albumin, the basis for the EpInex G1A® Rapid Diabetes Monitoring Index Test, has made significant advances in the past several months. The patent was published by WIPO, the World Intellectual Property Organization, on April 7th. Our European National Phase Patent Application for the European Community was filed June 15th, and can be viewed on the *espacenet* website. The application for a Canadian patent was filed on September 22nd of 2004. A patent application for Japan is pending.



WIPO Patent Application



European Community Patent Application

Corporate Office:
EpInex Diagnostics, Inc.
2815 McGaw Avenue
Irvine, California 92614 USA
www.epinex.com

Corporate Finance:
Jeff Byrd, Vice President
Toll Free: (866) 592-3746
jeff@epinex.com



EPINEX DIAGNOSTICS INC.
CREATING A REVOLUTION IN BIOTECH-BASED DIAGNOSTICS

Epinex Open House

Epinex held its first Open House on Friday, September 23rd, at our facility in Irvine. Company President Asad Zaidi invited shareholders, collaborators, investors and friends to “join us as we celebrate moving forward into the next phases of our company’s growth.” The catered event included demonstrations of Company projects and tours of the facility. Attended by approximately 50 guests, the successful event included investors who flew in from as far away as New York and Seattle.



Epinex President Asad Zaidi leads a tour of the facility



Brian Kirk from Biodot, a strategic partner with Epinex, explains nanoliter dispensing technology



Dr. Ping Wang and Asad explain the functions of the wet and dry labs during a tour of the facility



Dr. Henry Smith, Chief Technology Officer for Epinex



Jeff Byrd, Vice-President for Corporate Finance, discusses the Company with guests



Asad with Mr. Ike Suri of Trilennia Investment Group and Azra Zaidi, Epinex Director of Research and Development



EPINEX DIAGNOSTICS INC.
CREATING A REVOLUTION IN BIOTECH-BASED DIAGNOSTICS